Summary: In Indian children with type 1 diabetes, 12 weeks of oligofructose-enriched inulin enriched short-chain fatty acid-producing gut bacteria but did not improve glycaemic control (HbA1c 9.8% vs 10.6%, NS) compared with placebo, and was well tolerated.
PICO Summary
| Element | Detail |
|---|---|
| Population | Indian children aged 8–18 with established type 1 diabetes (n=68 randomised, 61 completed). |
| Intervention | 8 g/day oligofructose-enriched inulin for 12 weeks. |
| Comparison | Isocaloric maltodextrin placebo. |
| Outcome | No significant HbA1c difference (prebiotic 9.8 ± 1.4% vs placebo 10.6 ± 2.5%; p>0.05). Significant enrichment of SCFA-producing taxa (Intestinibacter, Megasphaera, Prevotella_2, Agathobacter) and beneficial families; alpha and beta diversity stable. Well tolerated. |
Prebiotic inulin in childhood T1DM
Pilot RCT · type 1 diabetes · 12 weeks
Twelve weeks of prebiotic inulin enriched SCFA-producing gut bacteria but did not lower HbA1c versus placebo. A microbiome signal without a glycaemic one in established type 1 diabetes.
Expert Commentary
The gut microbiome is one of those fields where the preclinical promise has always run far ahead of what I can offer a child in clinic, so I read pilot trials like this with interest but disciplined expectations. The honest verdict is that it did exactly what its biology predicted and nothing more: the prebiotic reshaped the microbiome toward SCFA-producing species, yet HbA1c did not move, and in established type 1 diabetes, where beta cells are already gone to autoimmunity, I would not have expected it to. That is not a failure so much as a reality check on where microbiome modulation can and cannot help. The limitations matter here, chiefly the small pilot size and the short twelve weeks, which is nowhere near long enough to test the more plausible hypothesis that any benefit is immunological and slow. Can I use this with my patients? Not as anything that changes glycaemic management, and I would be careful not to let a family infer that a supplement helps their child’s sugars. I might support prebiotic-rich foods as general gut health, while being clear the diabetes case is unproven. I would want a long-term trial powered for immune and inflammatory endpoints before saying more.
References
Tamahane V, Shah N, Kajale N, et al. Effect of prebiotic intervention on glycemic control and gut microbiome profile in Indian children with type 1 diabetes mellitus (T1DM): a pilot randomised control trial. Endocrine. 2026;91(1). doi:10.1007/s12020-026-04657-w